Form 4: TENAX Director Davidson Reports Equity Holdings

TENAX Therapeutics Director Michael H. Davidson filed a Form 4 detailing his beneficial ownership of common stock and various derivative securities, including new stock options and warrants.

Summary

• Michael H. Davidson, a Director of TENAX THERAPEUTICS, INC. (TENX), filed a Form 4 statement of changes in beneficial ownership.
• The filing reports beneficial ownership of 2,881 shares of common stock directly.
• A new stock option grant for 30,000 shares with an exercise price of $13.3 was reported with a transaction date of January 9, 2026, exercisable from January 9, 2027, and expiring January 9, 2036.
• Other reported derivative holdings include stock options for 4 shares (exercise price $3,200, exercisable 06/10/2022, expiring 06/10/2031), 4 shares (exercise price $992, exercisable 06/09/2023, expiring 06/09/2032), 100,000 shares (exercise price $5.94, exercisable 12/10/2025, expiring 12/10/2034), and 80,000 shares (exercise price $5.75, exercisable 07/01/2026, expiring 07/01/2035).
• Pre-funded warrants for 47,500 shares (exercise price $0.01, exercisable 08/08/2024, no expiration date) and warrants for 25,000 shares (exercise price $4.5, exercisable 08/08/2024) were also reported.
• The 25,000 warrants will expire on the earlier of (i) thirty trading days following the initial public announcement of topline data from the company's Phase 3 LEVEL Study (NCT05983250), (ii) proportionally upon the exercise of the reporting person's pre-funded warrant issued on August 8, 2024, if prior to the Topline Data Announcement, or (iii) August 8, 2029.

Sentiment

Score: 6

Explanation: The filing reports a director's beneficial ownership and the grant of new stock options, which generally aligns management's interests with shareholders. It does not contain any negative transactions like sales, indicating a neutral to slightly positive sentiment.

Positives

• Director Michael H. Davidson received a new grant of 30,000 stock options, aligning his interests with shareholders.
• The director holds a significant number of derivative securities, indicating a vested interest in the company's future performance.

Risks

• The expiration of 25,000 warrants is contingent on the timing and outcome of topline data from the Phase 3 LEVEL Study (NCT05983250), introducing clinical trial risk.

Future Outlook

The expiration of certain warrants is linked to the initial public announcement of topline data from the company's Phase 3 LEVEL Study (NCT05983250), indicating a future milestone for the company.

Industry Context

Form 4 filings are standard for publicly traded companies to report insider transactions. For biotech/pharma companies like TENAX, the mention of a Phase 3 study (LEVEL Study, NCT05983250) places the company within the clinical development stage, where trial results are critical for future valuation and strategic direction.

Related Party Transactions

• The grant of stock options and warrants to Michael H. Davidson, a Director, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: May view the new equity grants to a director as a positive signal of alignment between management and shareholder interests, potentially increasing confidence in the company's future.

Next Steps

• Monitoring the initial public announcement of topline data from the Phase 3 LEVEL Study (NCT05983250) as it impacts the expiration of certain warrants.

Key Dates

Recommendation

A Form 4 filing detailing director equity grants provides insight into insider holdings and compensation but typically does not offer sufficient information to warrant a strong buy or sell recommendation without broader financial context or significant, unusual transaction activity. This filing appears routine.

Keywords

TENAX Therapeutics, TENX, Form 4, insider transaction, stock options, warrants, beneficial ownership, director compensation, equity grants, LEVEL Study, NCT05983250